Trevi Therapeutics Files Q2 2024 10-Q
Ticker: TRVI · Form: 10-Q · Filed: Aug 8, 2024 · CIK: 1563880
Sentiment: neutral
Topics: 10-Q, financials, stock-plans, debt
TL;DR
Trevi Therapeutics dropped its Q2 10-Q. Financials look steady, check stock plans.
AI Summary
Trevi Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter. Key financial data and disclosures related to the company's stock plans and debt are included.
Why It Matters
This filing provides investors with the latest financial health and operational status of Trevi Therapeutics, crucial for understanding its current market position and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Trevi Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-06-30 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2024-08-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Filer of the 10-Q
- 2024-06-30 (date) — End of reporting period
- 2024-08-08 (date) — Filing date
- SiliconValleyBankTermLoanMember (financial_instrument) — Mentioned debt instrument
FAQ
What is the primary business of Trevi Therapeutics, Inc.?
Trevi Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
What is the fiscal year end for Trevi Therapeutics?
The fiscal year end for Trevi Therapeutics is December 31.
What specific stock incentive plans are mentioned in the filing?
The filing mentions the 'TwoThousandAndNineteenStockIncentivePlanMember', 'TwoThousandAndNineteenStockOptionAndGrantPlanMember', 'TwoThousandAndNineteenEmployeeStockPurchasePlanMember', and 'TwoThousandTwelveStockIncentivePlanMember'.
What debt instrument is referenced in the filing?
The filing references the 'SiliconValleyBankTermLoanMember' along with its 'ThirdAmendmentMember'.
What is the SEC file number for Trevi Therapeutics?
The SEC file number for Trevi Therapeutics is 001-38886.
Filing Stats: 4,479 words · 18 min read · ~15 pages · Grade level 17.6 · Accepted 2024-08-08 16:13:36
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share TRVI The Nasdaq
Filing Documents
- trvi-20240630.htm (10-Q) — 2233KB
- trvi-ex31_1.htm (EX-31.1) — 15KB
- trvi-ex31_2.htm (EX-31.2) — 15KB
- trvi-ex32_1.htm (EX-32.1) — 9KB
- trvi-ex32_2.htm (EX-32.2) — 9KB
- 0000950170-24-093983.txt ( ) — 8502KB
- trvi-20240630.xsd (EX-101.SCH) — 1137KB
- trvi-20240630_htm.xml (XML) — 1466KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.
Controls and Procedures
Controls and Procedures 28 PART II. OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 28 Item 1A.
Risk Factors
Risk Factors 28 Item 5. Other Information 70 Item 6. Exhibits 70
—FINANCI AL INFORMATION
PART I—FINANCI AL INFORMATION
Condensed Consolidated Financi al Statements
Item 1. Condensed Consolidated Financi al Statements. Trevi Therapeutics, Inc. Condensed Consolida ted Balance Sheets (Amounts in thousands, except share and per share amounts) June 30, 2024 December 31, 2023 Assets Unaudited Current assets: Cash and cash equivalents $ 12,963 $ 32,397 Marketable securities 56,532 50,574 Prepaid expenses 1,804 3,621 Other current assets 830 955 Total current assets 72,129 87,547 Operating lease right-of-use assets 1,029 1,137 Finance lease right-of-use assets 181 206 Property, equipment and leasehold improvements, net 198 216 Other non-current assets 273 297 Total assets $ 73,810 $ 89,403 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,511 $ 1,809 Accrued expenses 4,932 3,709 Operating lease liabilities 216 184 Finance lease liabilities 93 122 Total current liabilities 6,752 5,824 Operating lease liabilities 884 1,001 Finance lease liabilities — 31 Total liabilities 7,636 6,856 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock: $ 0.001 par value; 5,000,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued or outstanding at June 30, 2024 and December 31, 2023. — — Common stock: $ 0.001 par value; 200,000,000 shares authorized at June 30, 2024 and December 31, 2023; and 72,591,917 and 68,283,699 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively. 73 68 Additional paid-in capital 328,573 321,642 Accumulated other comprehensive loss ( 84 ) ( 29 ) Accumulated deficit ( 262,388 ) ( 239,134 ) Total stockholders' equity 66,174 82,547 Total liabilities and stockholders' equity $ 73,810 $ 89,403 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Trevi Therapeutics, Inc. Condensed